What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings

Zacks
Ouvrir sur Zacks
What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings

Analysts on Wall Street project that TransMedics (TMDX) will announce quarterly earnings of $0.27 per share in its forthcoming report, representing a decline of 59.1% year over year. Revenues are projected to reach $181.81 million, increasing 26.4% from the same quarter last year.

The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

In light of this perspective, let's dive into the average estimates of certain TransMedics metrics that are commonly tracked and forecasted by Wall Street analysts.

The consensus among analysts is that 'Revenue- Service' will reach $74.65 million. The estimate indicates a change of +33% from the prior-year quarter.

The consensus estimate for 'Revenue- Net Product' stands at $109.20 million. The estimate indicates a year-over-year change of +24.6%.

It is projected by analysts that the 'OCS transplant revenue- United States- Total' will reach $176.03 million. The estimate indicates a year-over-year change of +26.6%.

According to the collective judgment of analysts, 'OCS transplant revenue- All other countries- Total' should come in at $4.63 million. The estimate points to a change of +27.5% from the year-ago quarter.

View all Key Company Metrics for TransMedics here>>>

Over the past month, TransMedics shares have recorded returns of -16.1% versus the Zacks S&P 500 composite's -2% change. Based on its Zacks Rank #3 (Hold), TMDX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
TransMedics Group, Inc. (TMDX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research